title: Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.
abstract: BACKGROUND
  New molecular profiling technologies can aid in analysis of small pathologic samples obtained by minimally invasive biopsy and may enable the discovery of key biomarkers synergistic with anatomopathologic analysis related to prognosis, therapeutic response, and innovative target validation. Thus proteomic analysis at the histologic level in healthy and pathologic settings is a major issue in the field of clinical proteomics.
  
  
  METHODS
  We used surface-enhanced laser desorption ionization-time-of-flight mass spectrometry (SELDI-TOF MS) technology with surface chromatographic subproteome enrichment and preservation of the spatial distribution of proteomic patterns to detect discrete modifications of protein expression. We performed in situ proteomic profiling of mouse tissue and samples of human cancer tissue, including brain and lung cancer.
  
  
  RESULTS
  This approach permitted the discrimination of glioblastomas from oligodendrogliomas and led to the identification of 3 potential markers.
  
  
  CONCLUSIONS
  Direct tissue proteomic analysis is an original application of SELDI-TOF MS technology that can expand the use of clinical proteomics as a complement to the anatomopathological diagnosis.
authors.affiliation: INSERM U318, Université de Grenoble, Department of Neurosurgery, Centre Hospitalier Universitaire Grenoble, France.
authors.forename: Ali
authors.initials: A
authors.lastname: Bouamrani
authors.forename: Jessica
authors.initials: J
authors.lastname: Ternier
authors.forename: David
authors.initials: D
authors.lastname: Ratel
authors.forename: Alim-Louis
authors.initials: AL
authors.lastname: Benabid
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Issartel
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Brambilla
authors.forename: François
authors.initials: F
authors.lastname: Berger
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D016543:Central Nervous System Neoplasms / Q000737:chemistry* / Q000175:diagnosis; D005909:Glioblastoma / Q000737:chemistry* / Q000175:diagnosis; D006801:Humans; D051379:Mice; D009837:Oligodendroglioma / Q000737:chemistry* / Q000175:diagnosis; D009928:Organ Specificity; D040901:Proteomics / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*
chemical_list: D015415:Biomarkers